The global multiple sclerosis (MS) community is celebrating a major milestone: Professor Ludwig Kappos has been named the 2025 recipient of the Charcot Award, the highest international recognition for lifetime achievement in MS research, presented by the Multiple Sclerosis International Federation (MSIF).
A Driving Force in MS Progress
Over the past 30+ years, Professor Kappos has shaped nearly every aspect of how MS is diagnosed, treated, and understood. His work has helped redefine standards of care, accelerate drug development, and deepen our understanding of disease progression and the ways we measure disease activity.
“The inspiration I got throughout decades of my professional career came from people with MS, and the continuous motivation they gave us.” says Professor Kappos in a video on the MSIF YouTube channel.
One of the most influential experts in the field, Professor Kappos is deeply committed to inspiring and mentoring the next generation of MS researchers.
Behind Today’s Leading Treatments
Many of today’s most widely used MS therapies were developed through clinical trials in which Professor Kappos served as principal investigator or as a member of the steering committee. From interferons to next-generation treatments like ocrelizumab and siponimod, his research has influenced how doctors manage both relapsing and progressive forms of MS – paving the way for more personalised treatment options.
Rethinking How MS Is Measured
Beyond treatment development, Professor Kappos has also been a leading advocate for the concept of PIRA (Progression Independent of Relapse Activity), playing a key role in reshaping how MS progression is defined and assessed. He has advanced the use of digital tools, biomarkers, and imaging in MS care.
A Community Celebrates
His research – together with the work of his team – has set new benchmarks in clinical trial design, imaging, and MS treatment. This award recognises not only an exceptional career, but decades of progress made possible by their shared dedication and unwavering commitment.
Don’t miss the Charcot Lecture at ECTRIMS 2025 during the Plenary Session 2.